Events|

Connect with SHL at Drug Delivery Partnerships 2018

Press Release 201712 Ddp2018

SHL is exhibiting at the 2018 Drug Delivery Partnerships (DDP) conference in Florida from January 22-24 to present its innovative drug delivery devices and its commercialization solutions for final assembly, labeling, and packaging.

“DDP is an event that has for the past two decades been an important meeting place for drug delivery leaders. With the increased use of biologic and biosimilar formulations to treat chronic indications, SHL’s safe and reliable self-injection offerings meet the industry’s demand for efficient drug delivery devices that are designed to improve treatment outcomes,” said Jamie Gould, Manager of Business Development at SHL Group.

During the event, SHL will introduce the groundbreaking Maggie®, a two-step cartridge-based autoinjector for high-volume injections built with SHL’s market-proven Needle Isolation Technology (NIT®). Also on display is Bertha®, a versatile autoinjector that can accommodate a wide range of fill volumes and viscosities.

SHL will also present its Molly® 2.25 autoinjector. Designed with the same robust features as the classic Molly® family of preconfigured devices, this high-volume variation is equally safe and intuitive, and offers the same flexibility and short development timelines for faster commercialization.

To find out more about SHL’s latest innovations and comprehensive solutions for device commercialization, visit Booth 301 at the PGA National Resort & Spa in Palm Beach Gardens, Florida.

About SHL

SHL Group is a world-leading solution provider in the design, development and manufacturing of advanced drug delivery devices such as autoinjectors, pen injectors and advanced inhaler systems. We also offer core competencies and services in the fields of medtech and patient care solutions. With locations in Taiwan, Switzerland, Sweden, China and the US, our experienced engineers and designers develop product enhancements as well as breakthrough drug delivery and patient care solutions for pharma and biotech clients globally. Significant investment in R&D has enhanced our broad pipeline of next-generation drug delivery systems that support ongoing innovations in drug development and digital healthcare. This includes advanced reusable and disposable injectors that can accommodate high volume and high viscosities and can be enhanced through digital implementations.

With over 4,000 employees worldwide, SHL Group consists of several distinct group companies:

SHL Medical designs, develops and manufactures advanced drug delivery devices, as well as provides final assembly, labeling and packaging services for leading pharmaceutical and biotech companies across the globe.

SHL Healthcare develops and manufactures equipment solutions for home, hospital and long term care use.

SHL Technologies provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

For additional information, visit www.shl.group

Share:

Related News